Gut bug may reveal who responds to prostate cancer drug

NCT ID NCT06242509

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a specific gut bacterium, Akkermansia muciniphila, can predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will collect stool and blood samples from 52 men over three months to track changes in the bacteria and compare them to treatment response. The goal is to find a simple, non-invasive way to identify who will benefit most from this therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple stool test to predict which prostate cancer patients will benefit from certain hormone therapies.
What could go wrong: This is a small, early-stage observational study (52 participants) that only looks for a link, not a proven treatment. The findings may not apply to all patients or lead to a practical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Hôpital Saint Louis AP-HP
RECRUITING

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.